Drug Discovery

The clinical reality of lineage plasticity allows prostate cancer cells to survive treatment by shedding their identity and adopting forms that do not require androgen. This phenomenon presents a persistent challenge in oncology, as traditional therapies predominantly target the androgen receptor

The relentless evolution of Mycobacterium tuberculosis into multi-drug-resistant and extensively drug-resistant strains has created a critical gap that current therapeutic pipelines are unable to fill. This biological arms race has forced the scientific community to confront the limitations of

Genetic blueprints have long been visualized as sleek, predictable spirals, yet the hidden reality of our DNA involves complex architectural knots that could hold the secret to dismantling the most aggressive forms of human cancer. While the Watson-Crick double helix remains the foundation of

The pharmaceutical landscape has shifted so dramatically that the most valuable breakthroughs are no longer found in the discovery of new biological targets but in the chemical bridges that connect them to therapeutic payloads. This evolution marks a departure from the historical reliance on

The medical community stands at a crossroads where the convenience of AI-designed diagnostics must be balanced against the rigorous demands of patient safety and survival statistics. As of the current count in 2026, the US Food and Drug Administration has authorized exactly 1,524 AI-enabled medical

The silent corridors of oncology wards are witnessing a profound transformation as sophisticated algorithms begin to solve biological puzzles that have baffled human researchers for decades. For many years, a specific diagnosis—Microsatellite Stable (MSS) bowel cancer—felt like hitting a dead end